Zheng Gang, Chang Qing, Zhang Yixiao, Liu Yashu, Ji Chao, Yang Honghao, Chen Liangkai, Xia Yang, Zhao Yuhong
Department of Clinical Epidemiology, Shengjing Hospital of China Medical University, China Medical University, Shenyang, China.
Key Laboratory of Precision Medical Research on Major Chronic Disease, Shenyang, China.
Aging Cell. 2025 Apr;24(4):e14453. doi: 10.1111/acel.14453. Epub 2024 Dec 24.
Little evidence exists regarding the associations between clinical parameter-based biological aging and the incidence and outcome of chronic kidney disease (CKD). Thus, we aimed to assess the associations between biological aging, genetic risk, and the risk of CKD, as well as investigate the impact of accelerated biological aging on life expectancy. 281,363 participants free of kidney diseases from the UK Biobank were included in this prospective study. Biological age was measured from clinical traits using the KDM-BA and PhenoAge algorithms, and the discrepancies from chronological age were defined as biological age accelerations. A polygenic score was calculated to indicate the genetic predisposition of the estimated glomerular filtration rate (eGFR). A cause-specific competing risk model was used to estimate hazard ratios (HRs) and the corresponding confidence intervals (CIs) of incident CKD. We found that individuals with more pronounced accelerations in biological age exhibited an elevated risk of developing CKD (HR, 1.90; 95% CI, 1.77-2.05 for KDM-BA acceleration and HR, 2.79; 95% CI, 2.58-3.01 for PhenoAge acceleration), with nonlinear relationships. Notably, there were positive additive interactions between biological aging and genetic risk on CKD risk. Among the CKD population, accelerated biological aging was associated with a further decline in life expectancy. Advanced biological aging may potentially increase the vulnerability to developing CKD in individuals aged midlife and beyond, particularly among those with high genetic risk for abnormal kidney function, and could reduce the life expectancy of CKD patients.
关于基于临床参数的生物衰老与慢性肾脏病(CKD)的发病率及预后之间的关联,目前证据较少。因此,我们旨在评估生物衰老、遗传风险与CKD风险之间的关联,并研究加速生物衰老对预期寿命的影响。本前瞻性研究纳入了英国生物银行中281,363名无肾脏疾病的参与者。使用KDM-BA和PhenoAge算法从临床特征测量生物年龄,并将其与实际年龄的差异定义为生物年龄加速。计算多基因评分以表明估计肾小球滤过率(eGFR)的遗传易感性。采用特定病因的竞争风险模型来估计CKD发病的风险比(HR)及相应的置信区间(CI)。我们发现,生物年龄加速更明显的个体发生CKD的风险升高(KDM-BA加速时,HR为1.90;95%CI为1.77-2.05;PhenoAge加速时,HR为2.79;95%CI为2.58-3.01),且呈非线性关系。值得注意的是,生物衰老与遗传风险在CKD风险方面存在正向相加相互作用。在CKD人群中,加速生物衰老与预期寿命的进一步下降相关。生物衰老进展可能会增加中年及以上个体患CKD的易感性,尤其是那些肾功能异常遗传风险高的个体,并可能缩短CKD患者的预期寿命。